Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients

被引:53
作者
Maeda, Ryo [1 ]
Yoshida, Junji [1 ]
Ishii, Genichiro [2 ]
Hishida, Tomoyuki [1 ]
Nishimura, Mitsuyo [1 ]
Nagai, Kanji [1 ]
机构
[1] Natl Canc Ctr Hosp E, Dept Thorac Oncol, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Dept Pathol, Chiba 2778577, Japan
关键词
VISCERAL PLEURAL INVASION; PATHOLOGICAL STAGE; VESSEL INVASION; ADJUVANT CHEMOTHERAPY; BLOOD-VESSEL; TNM STAGE; CARCINOMA; RECURRENCE; ADENOCARCINOMAS; CLASSIFICATION;
D O I
10.1136/thx.2010.141861
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
100201 [内科学];
摘要
Objective Intratumoral vascular invasion (IVI) in patients with non-small cell lung cancer (NSCLC) has been reported to be a strong independent predictor of recurrence, but it has not been incorporated in the TNM classifications including the latest 7th edition. The purpose of this study was to evaluate its significance as a risk factor for recurrence. Methods Between July 1992 and December 2006, 2295 consecutive patients with pathological T1-4N0-2 NSCLC underwent complete resection with systematic lymph node dissection at the National Cancer Center Hospital East. The recurrence-free proportion was estimated using the Kaplan-Meier method and differences were determined by the log rank test. Cox proportional hazard ratios were used to identify independent risk factors for recurrence. Results The proportion of recurrence-free patients at 5 years was 85.0% for patients without IVI and 51.5% for patients with IVI (p<0.001). On multivariate analyses, IVI proved to be an independently statistically significant risk factor for recurrence (HR 1.866, p<0.001). The recurrence-free proportion of patients with IVI was significantly lower than for patients without IVI in T1a (93.1% vs 69.3%, p<0.001), T1b (89.7% vs 62.7%, p<0.001), T2a (78.4% vs 53.0%, p<0.001), T2b (70.5% vs 46.4%, p=0.021) and T3 (53.1% vs 37.4%, p=0.031) subgroups. Conclusions In resected patients with T1-4N0-2 NSCLC, IVI was an independently significant risk factor for recurrence. IVI should be examined and its data collected to be considered for the next revision of the TNM staging system.
引用
收藏
页码:1092 / 1098
页数:7
相关论文
共 24 条
[1]
[Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs
[2]
Brechot JM, 1996, CANCER-AM CANCER SOC, V78, P2111, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2111::AID-CNCR11>3.0.CO
[3]
2-1
[4]
Bunker ML, 1999, AM J CLIN PATHOL, V112, P777
[5]
Eto T, 1996, CANCER, V77, P646, DOI 10.1002/(SICI)1097-0142(19960215)77:4<646::AID-CNCR10>3.0.CO
[6]
2-0
[7]
Elastosis in lung carcinoma: Immunohistochemical, ultrastructural and clinical studies [J].
Fukushima, M ;
Fukuda, Y ;
Kawamoto, M ;
Yamanaka, N .
PATHOLOGY INTERNATIONAL, 2000, 50 (08) :626-635
[8]
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[9]
HARPOLE DH, 1995, CANCER-AM CANCER SOC, V76, P787, DOI 10.1002/1097-0142(19950901)76:5<787::AID-CNCR2820760512>3.0.CO
[10]
2-Q